Janney Montgomery Scott LLC Has $2.39 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Janney Montgomery Scott LLC reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 29,321 shares of the medical equipment provider’s stock after selling 1,111 shares during the period. Janney Montgomery Scott LLC’s holdings in Hologic were worth $2,388,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Innealta Capital LLC bought a new stake in shares of Hologic in the 2nd quarter valued at $25,000. Wolff Wiese Magana LLC purchased a new position in Hologic in the third quarter valued at about $25,000. iA Global Asset Management Inc. bought a new stake in shares of Hologic in the first quarter valued at $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic in the second quarter worth about $37,000. Finally, Cromwell Holdings LLC lifted its position in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Leerink Partners cut their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Stock Performance

Shares of Hologic stock opened at $79.76 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 3.32 and a debt-to-equity ratio of 0.49. The firm has a market cap of $18.53 billion, a P/E ratio of 23.95, a P/E/G ratio of 2.48 and a beta of 0.98. The stock’s fifty day moving average price is $80.88 and its 200-day moving average price is $78.22. Hologic, Inc. has a 12 month low of $67.59 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period last year, the business earned $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.